New drugs and technologies, intravenous anaesthesia is on the move (again)

British Journal of Anaesthesia

Volumn 105, Issue 3, 2010, Pages 246-254

  Sneyd, J R ^a   Rigby Jones, A E ^a  

^a UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

anaesthetic techniques, i.v.; anaesthetics i.v., propofol; hypnotics benzodiazepine, midazolam; model, pharmacodynamic; model, pharmacokinetic

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ETOMIDATE; INTRAVENOUS ANESTHETIC AGENT;

ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; INTRAVENOUS ANESTHESIA; PROCEDURES; TRENDS;

ANESTHESIA, INTRAVENOUS; ANESTHETICS, INTRAVENOUS; DRUG DELIVERY SYSTEMS; ETOMIDATE; GABA-A RECEPTOR AGONISTS; HUMANS;

EID: 77956025805     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aeq190     Document Type: Review

References (63)

1. Scott RP, Saunders DA, Norman J. Propofol: clinical strategies for preventing the pain of injection. Anaesthesia 1988; 43: 492-494
2. Rau J, Roizen MF, Doenicke AW, O'Connor MF, Strohschneider U. Propofol in an emulsion of long- and medium-chain triglycerides: the effect on pain. Anesth Analg 2001; 93: 382-384
3. Thomas DV. Propofol supports bacterial growth. Br J Anaesth 1991; 66: 274
4. Bray R. Propofol infusion syndrome in children. Paediatr Anaesth 2008; 8: 491-499
5. Cremer OL, Moons KGM, Bouman EAC, Kruijswijk JE, de Smet A, Kalkman CJ. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet 2001; 357: 117-118
6. Sneyd JR. Excitatory events associated with propofol anaesthesia: a review. J R Soc Med 1992; 85: 288-291
7. Tuk B, van Oostenbruggen MF, Herben VM, Mandema JW, Danhof M. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. J Pharmacol Exp Ther 1999; 289: 1067-1074
8. Johnson TN, Rostami-Hodjegan A, Goddard JM, Tanner MS, Tucker GT. Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. Br J Anaesth 2002; 89: 428-437
9. Wiard RP, Feldman PL, Collins H et al. CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology 2007; 107: 60-66
10. Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A phase I SAD study evaluating the safety, pharmacokinetics and pharmacodynamics of CNS 7056. Anesthesiology 2009: A1603. Available from www.asaabstracts.com
11. Chernik DA, Gillings D, Laine H et al. Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: study with intravenous midazolam. J Clin Psychopharmacol 1990; 10: 244-251
12. Short acting anaesthetic/sedative CNS 7056 in a Phase IIa study in upper GI endoscopy. Available from www.paion.com (accessed January 5, 2010)
13. Kanamitsu N, Osaki T, Itsuji Y, Yoshimura M, Tsujimoto H, Soga M. Novel water-soluble sedative-hypnotic agents: isoindolin-1-one derivatives. Chem Pharm Bull (Tokyo) 2007; 55: 1682-1688
14. Rigby-Jones AE, Sneyd JR, Ohkura T, Tominaga H, Cross M. MR04A3 (aqueous 1.0% JM-1232(-)) pharmacokinetics and pharmacodynamics in man. Anesthesiology 2009: A464. Available from www.asaabstracts.com
15. Nishiyama T, Chiba S, Yamada Y. Antinociceptive property of intrathecal and intraperitoneal administration of a novel watersoluble isoindolin-1-one derivative, JM 1232 (-) in rats. Eur J Pharmacol 2008; 596: 56-61
16. Reddy RV, Moorthy SS, Dierdorf SF, Deitch Rd Jr, Link L. Excitatory effects and electroencephalographic correlation of etomidate, thiopental, methohexital, and propofol. Anesth Analg 1993; 77: 1008-1011
17. Ledingham IMA, Finlay WEI, Watt I et al. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983; 321: 1270
18. Ray DC, Hay AW, McKeown DW. Induction drug and outcome of patients admitted to the intensive care unit after emergency laparotomy. Eur J Anaesth 2010; 27: 481-485
19. Bloomfield R, Noble DW. Etomidate and fatal outcome-even a single bolus dose may be detrimental for some patients. Br J Anaesth 2006; 97: 116-117
20. Cuthbertson BH, Sprung CL, Annane D et al. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med 2009; 35: 1868-1876
21. Jabre P, Combes X, Lapostolle F et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374: 293-300
22. Egan TD. Is anesthesiology going soft?: trends in fragile pharmacology. Anesthesiology 2009; 111: 229-230
23. Forman SA, Stewart D, Husain S et al. MTS-etomidate selectively reacts with cysteines in the GABA A receptor etomidate binding site. Anesthesiology 2009: A1382. Available from www. asaabstracts.com
24. Stewart DS, Husain SS, Miller KW, Forman SA. MTS-etomidate selectively reacts within the GABAA receptor etomidate binding site. Biophys J 2009; 96: 487a-488a
25. Cotten JF, Husain SS, Forman SA et al. Methoxycarbonyletomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology 2009; 111: 240-249
26. Pitsiu M, Wilmer A, Bodenham A et al. Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. Br J Anaesth 2004; 92: 493-503
27. Cotten JF, Forman SA, Laha JK et al. Carboetomidate: A pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology 2010; 112: 637-644
28. Raines D, Forman S, Miller K, Husain S, Cotten J. Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties. 2009. Application No. WO2009US38872. World Intellectual Property Organization
29. Egan TD, Shafer SL, Jenkins TE, Beattie DT, Jaw-Tsai SS. The pharmacokinetics and pharmacodynamics of THRX-918661, a novel sedative/hypnotic agent. Anesthesiology 2003; A516. Available from www.asaabstracts.com
30. Sneyd JR. Recent advances in intravenous anaesthesia. Br J Anaesth 2004; 93: 725-736
31. Jenkins TE. Stereoisomers propofol therapeutic compounds. Patent WO/2008/141097. 2008. Application No. PCT/US 2008/ 063082
32. James R, Glen JB. Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents. J Med Chem 1980; 23: 1350-1357
33. Siegel LC, Konstantatos A. PF0713 produced rapid induction of general anesthesia without injection pain in a phase 1 study. Anesthesiology 2009: A463.Available fromwww.asaabstracts.com
34. Absalom AR, Mani V, De Smet T, Struys MMRF. Pharmacokinetic models for propofol-defining and illuminating the devil in the detail. Br J Anaesth 2009; 103: 26-37
35. Pambianco DJ, Whitten CJ, Moerman A, Struys MM, Martin JF. An assessment of computer-assisted personalized sedation: a sedation delivery system to administer propofol for gastrointestinal endoscopy. Gastrointest Endosc 2008; 68: 542-547
36. Goudra BG, Mandel JE. Target-controlled infusions/patientcontrolled sedation. Tech Gastrointest Endosc 2009; 11: 181-187
37. Barron DW, Dundee JW. The recently introduced rapidly acting barbiturates; a review and critical appraisal in relation to thiopentone. Br J Anaesth 1961; 33: 81-91
38. Bell MD, Goodchild CS. Hypertrophic obstructive cardiomyopathy in combination with a prolapsing mitral valve. Anaesthesia for surgical correction with propofol. Anaesthesia 1989; 44: 409-411
39. Safe Anaesthesia Liaison Group. Guaranteeing drug delivery in total intravenous anaesthesia. 2009. Available from www.aagbi. org/news/docs/tiva- infonov09.pdf
40. Sneyd JR, Whaley A, Dimpel HL, Andrews CJ. An open, randomized comparison of alfentanil, remifentanil and alfentanil followed by remifentanil in anaesthesia for craniotomy. Br J Anaesth 1998; 81: 361-364
41. Vuyk J, Lim T, Engbers FH, Burm AG, Vletter AA, Bovill JG. The pharmacodynamic interaction of propofol and alfentanil during lower abdominal surgery in women. Anesthesiology 1995; 83: 8-22
42. Kern SE, Xie G, White JL, Egan TD. A response surface analysis of propofol-remifentanil pharmacodynamic interaction in volunteers. Anesthesiology 2004; 100: 1373-1381
43. Fennelly ME, Powell H, Galletly DC, Whitwam JG. Midazolam sedation reversed with flumazenil for cardioversion. Br J Anaesth 1992; 68: 303-305
44. Breheny FX. Reversal of midazolam sedation with flumazenil. Crit Care Med 1992; 20: 736-739
45. Vuyk J, Hennis PJ, Burm AG, de Voogt JW, Spierdijk J. Comparison of midazolam and propofol in combination with alfentanil for total intravenous anesthesia. Anesth Analg 1990; 71: 645-650
46. Raeder JC, Hole A, Arnulf V, Grynne BH. Total intravenous anaesthesia with midazolam and flumazenil in outpatient clinics. A comparison with isoflurane or thiopentone. Acta Anaesthesiol Scand 1987; 31: 634-641
47. Forrest P, Galletly DC. Comparison of propofol and antagonised midazolam anaesthesia for day-case surgery. Anaesth Intensive Care 1987; 15: 394-401
48. Thornton C, Barrowcliffe MP, Konieczko KM et al. The auditory evoked response as an indicator of awareness. Br J Anaesth 1989; 63: 113-115
49. Thornton C, Konieczko KM, Knight AB et al. Effect of propofol on the auditory evoked response and oesophageal contractility. Br J Anaesth 1989; 63: 411-417
50. Schwender D, Golling W, Klasing S, Faber-Zullig E, Poppel E, Peter K. Effects of surgical stimulation on midlatency auditory evoked potentials during general anaesthesia with propofol/ fentanyl, isoflurane/fentanyl and flunitrazepam/fentanyl. Anaesthesia 1994; 49: 572-578
51. Russell IF. Midazolam-alfentanil: an anaesthetic? An investigation using the isolated forearm technique. Br J Anaesth 1993; 70: 42-46
52. Heidegger T, Nuebling M, Saal D, Kreienbuhl G. Patient-centred outcomes in clinical research: does it really matter? Br J Anaesth 2008; 100: 1-3
53. Fisher DM. Surrogate end points. Anesthesiology 1994; 81: 795-796
54. Biccard BM, Sear JW, Foex P. Meta-analysis of the effect of heart rate achieved by perioperative beta-adrenergic blockade on cardiovascular outcomes. Br J Anaesth 2008; 100: 23-28
55. Giglio MT, Marucci M, Testini M, Brienza N. Goal-directed haemodynamic therapy and gastrointestinal complications in major surgery: a meta-analysis of randomized controlled trials. Br J Anaesth 2009; 103: 637-646
56. Fukuda S, Warner DS. Cerebral protection. Br J Anaesth 2007; 99: 10-17
57. Piriou V, Mantz J, Goldfarb G et al. Sevoflurane preconditioning at 1 MAC only provides limited protection in patients undergoing coronary artery bypass surgery: a randomized bi-centre trial. Br J Anaesth 2007; 99: 624-631
58. Melamed R, Bar-Yosef S, Shakhar G, Shakhar K, Ben-Eliyahu S. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesth Analg 2003; 97: 1331-1339
59. Deegan CA, Murray D, Doran P, Ecimovic P, Moriarty DC, Buggy DJ. Effect of anaesthetic technique on oestrogen receptor-negative breast cancer cell function in vitro. Br J Anaesth 2009; 103: 685-690
60. Wilder RT, Flick RP, Sprung J et al. Early exposure to anesthesia and learning disabilities in a population-based birth cohort. Anesthesiology 2009; 110: 796-804
61. Marsh B, White M, Morton N, Kenny GN. Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth 1991; 67: 41-48
62. Greenblatt DJ, Ehrenberg BL, Culm KE et al. Kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions. J Clin Pharmacol 2004; 44: 605-611
63. Short TG, Chui PT. Propofol and midazolam act synergistically in combination. Br J Anaesth 1991; 67: 539-545